Imeglimin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Imeglimin
DrugBank Accession Number
DB12509
Background

Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 155.205
Monoisotopic: 155.117095439
Chemical Formula
C6H13N5
Synonyms
  • Imeglimin
  • Imeglimina
  • Iméglimine
  • Imegliminum
External IDs
  • EMD-387008
  • EMD387008

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

ATC Codes
A10BX15 — Imeglimin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazines
Sub Class
Aminotriazines
Direct Parent
Aminotriazines
Alternative Parents
1,3,5-triazines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Hydrocarbon derivatives / Amines
Substituents
1,3,5-triazine / Aliphatic heteromonocyclic compound / Amine / Aminotriazine / Azacycle / Carboximidamide / Guanidine / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
UU226QGU97
CAS number
775351-65-0
InChI Key
GFICWFZTBXUVIG-SCSAIBSYSA-N
InChI
InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
IUPAC Name
(6R)-N4,N4,6-trimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
SMILES
C[C@@H]1NC(N)=NC(=N1)N(C)C

References

General References
Not Available
PubChem Compound
24812808
PubChem Substance
347828740
ChemSpider
26232690
ZINC
ZINC000034380900
Wikipedia
Imeglimin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus1
1CompletedOtherHealthy Volunteers (HV)1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentHepatic Impairment1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.63 mg/mLALOGPS
logP-0.92ALOGPS
logP-0.69Chemaxon
logS-1.5ALOGPS
pKa (Strongest Acidic)17.1Chemaxon
pKa (Strongest Basic)10.21Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.01 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity43.29 m3·mol-1Chemaxon
Polarizability16.62 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9600000000-2a1fdbaa8a5db9a2f5a1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-d161813c090e0bd2f439
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-020661d375f167e2b644
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-1900000000-026d0a3d8d829c06954c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0007-9400000000-fadcf870d446fd5e6adb
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0007-9000000000-77ce7b6d7adb8912d81c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-0f7afb34355c9ea642b1
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-136.7576871
predicted
DarkChem Lite v0.1.0
[M-H]-134.32848
predicted
DeepCCS 1.0 (2019)
[M+H]+136.7523871
predicted
DarkChem Lite v0.1.0
[M+H]+136.72406
predicted
DeepCCS 1.0 (2019)
[M+Na]+136.4036871
predicted
DarkChem Lite v0.1.0
[M+Na]+142.99596
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:40 / Updated at February 21, 2021 18:53